|
|
|
|
|
Detail |
| hsa-miR-17-5p |
|
Unspecified |
WITHDRAWN:MicroRNA profile in peripheral blood T cells of patients with primary biliary cirrhosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
MYCN regulates oncogenic MicroRNAs in neuroblastoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
MicroRNAs: novel regulators involved in the pathogenesis of Psoriasis? |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
A microRNA cluster as a target of genomic amplification in malignant lymphoma. |
2005 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. |
2006 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. |
2007 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. |
2009 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer |
2009 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Deregulated expression of miR-106a predicts survival in human colon cancer patients. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. |
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.
|
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM.
|
2008 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. |
2009 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Over- and under-expressed microRNAs in human colorectal cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Causal |
Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. |
2009 |
|
|
|
|
|
|
| hsa-miR-17-5p |
|
Unspecified |
Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. |
2009 |
|
|
|
|
|
|